Q4 2025 AxoGen Inc Earnings Call Transcript

Feb 24, 2026 / 01:00 PM GMT

Release Date Price: €29.4 (+1.38%)

Transcript 10-K8-K

Key Points

Positve

Axogen Inc (AXGN) achieved a significant revenue growth of 21.3% year-over-year in Q4 2025, with full-year revenue increasing by 20.2% to $225.2 million.
The company reached a financial inflection point, generating positive cash flow and improving profitability, with adjusted EBITDA growing 41% to $27.9 million.
Axogen Inc (AXGN) successfully completed an upsized public offering, raising $133.3 million in net proceeds, which enhanced their financial flexibility.
The FDA approved the biologics license application for Avance, making it the first and only FDA-approved biologic therapeutic for treating peripheral nerve discontinuities, with 12 years of market exclusivity.
Axogen Inc (AXGN) expanded its commercial organization significantly, adding sales representatives and regional directors across various markets, indicating strong market development progress.

Negative

Gross margin decreased to 74.1% in Q4 2025 from 76.1% in the same period last year, impacted by higher product costs and one-time costs related to FDA BLA approval.
Operating expenses increased significantly, with a 64.6% rise in general and administrative expenses in Q4 2025 compared to the previous year.
Net loss for Q4 2025 was $13.2 million, compared to a net income of $500,000 in Q4 2024, indicating a decline in profitability.
The company faces challenges in achieving full market coverage, particularly in extremities and breast markets, requiring further expansion of the sales force.
Despite the FDA approval, the transition to biologic products is expected to carry higher costs, potentially impacting gross margins in the short term.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AXGN.OQ - AxoGen Inc
Q4 2025 AxoGen Inc Earnings Call
Feb 24, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, everyone. Joining me on today's call is Michael Dale, Axelgen's Chief Executive Officer and director, and Lindsay Hartley, Chief Financial Officer. Michael will discuss 4th quarter and full year 2025 financial results and corporate highlights. Lindsay will then provide details on financial performance, guidance, and overall outlook for the year.

This will be followed by a question-and-answer session.

Today's call and presentation is being broadcast live via webcast, which is available on the investor section of Axelgen's website.

Following the end of the live call, a replay will be available in the investors section of the company's website at www.axogenic.com.

Before we begin, I'd like to remind you

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.